MoonLake Immunotherapeutics (MLTX) Total Liabilities (2020 - 2026)

MoonLake Immunotherapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $146.4 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 48.31% year-over-year to $146.4 million; the TTM figure through Mar 2026 stood at $146.4 million (up 48.31% YoY), while the FY2025 annual figure was $120.0 million, up 388.76% from the prior year.
• Total Liabilities was $146.4 million for Q1 2026 at MoonLake Immunotherapeutics, up from $120.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $206.8 million in Q1 2022 to a low of $3.9 million in Q2 2022.
• Historically, Total Liabilities has averaged $54.6 million across 5 years, with a median of $14.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 4962.8% in 2022, then plunged 96.28% in 2023.
• A 5-year view of Total Liabilities shows it stood at $8.1 million in 2022, then soared by 61.57% to $13.0 million in 2023, then soared by 88.07% to $24.5 million in 2024, then soared by 388.76% to $120.0 million in 2025, then climbed by 22.01% to $146.4 million in 2026.
• The last three Total Liabilities figures came in at $146.4 million (Q1 2026), $120.0 million (Q4 2025), and $123.1 million (Q3 2025), per Business Quant data.